The prevalence of TP53 mutations is typically extremely high (up to 50–70% in AML with complex karyotype [10–12]) in this population and the efficacy of HMA may reflect a TP53-independent mechanism of action. The gene discussed is TP53; the disease is acute myeloid leukemia.